{
  "video_id": "j4f5SwVxaxA",
  "title": "Ventricular assist device",
  "json": [
    {
      "index": 1,
      "start_time": 0.0,
      "end_time": 4668.0,
      "text": "A ventricular assist device is an electromechanical circulatory device"
    },
    {
      "index": 2,
      "start_time": 4668.0,
      "end_time": 10012.0,
      "text": "that is used to partially or completely replace the function of a failing heart."
    },
    {
      "index": 3,
      "start_time": 10012.0,
      "end_time": 15154.0,
      "text": "The function of VADs differs from that of artificial cardiac pacemakers. Some"
    },
    {
      "index": 4,
      "start_time": 15154.0,
      "end_time": 20228.0,
      "text": "VADs are intended for short term use, typically for patients recovering from"
    },
    {
      "index": 5,
      "start_time": 20228.0,
      "end_time": 25302.0,
      "text": "heart attacks or heart surgery, while others are intended for long-term use,"
    },
    {
      "index": 6,
      "start_time": 25302.0,
      "end_time": 30105.0,
      "text": "typically for patients suffering from advanced congestive heart failure."
    },
    {
      "index": 7,
      "start_time": 30105.0,
      "end_time": 35044.0,
      "text": "VADs are distinct from artificial hearts, which are designed to completely"
    },
    {
      "index": 8,
      "start_time": 35044.0,
      "end_time": 40185.0,
      "text": "take over cardiac function and generally require the removal of the patient&#39;s"
    },
    {
      "index": 9,
      "start_time": 40185.0,
      "end_time": 45056.0,
      "text": "heart. VADs are designed to assist either the right or left ventricle, or"
    },
    {
      "index": 10,
      "start_time": 45056.0,
      "end_time": 49792.0,
      "text": "both at once. The type that is used depends primarily on the underlying"
    },
    {
      "index": 11,
      "start_time": 49792.0,
      "end_time": 55069.0,
      "text": "heart disease and the pulmonary arterial resistance that determines the load on"
    },
    {
      "index": 12,
      "start_time": 55069.0,
      "end_time": 58993.0,
      "text": "the right ventricle. LVADs are most commonly used, but when"
    },
    {
      "index": 13,
      "start_time": 58993.0,
      "end_time": 64202.0,
      "text": "pulmonary arterial resistance is high, right ventricular assistance may become"
    },
    {
      "index": 14,
      "start_time": 64202.0,
      "end_time": 69412.0,
      "text": "necessary. Long term VADs are normally used to keep patients alive with a good"
    },
    {
      "index": 15,
      "start_time": 69412.0,
      "end_time": 74418.0,
      "text": "quality of life while they wait for a heart transplantation. However, LVADs"
    },
    {
      "index": 16,
      "start_time": 74418.0,
      "end_time": 79357.0,
      "text": "are sometimes used as destination therapy, meaning they will never undergo"
    },
    {
      "index": 17,
      "start_time": 79357.0,
      "end_time": 83078.0,
      "text": "heart transplant, and sometimes as a bridge to recovery."
    },
    {
      "index": 18,
      "start_time": 83078.0,
      "end_time": 87543.0,
      "text": "In the last few years, VADs have improved significantly in terms of"
    },
    {
      "index": 19,
      "start_time": 87543.0,
      "end_time": 91264.0,
      "text": "providing survival and quality of life among recipients."
    },
    {
      "index": 20,
      "start_time": 91264.0,
      "end_time": 92211.0,
      "text": "Design = Pumps="
    },
    {
      "index": 21,
      "start_time": 92211.0,
      "end_time": 97149.0,
      "text": "The pumps used in VADs can be divided into two main categories – pulsatile"
    },
    {
      "index": 22,
      "start_time": 97149.0,
      "end_time": 102359.0,
      "text": "pumps, that mimic the natural pulsing action of the heart, and continuous flow"
    },
    {
      "index": 23,
      "start_time": 102359.0,
      "end_time": 107094.0,
      "text": "pumps. Pulsatile VADs use positive displacement pumps. In some of these"
    },
    {
      "index": 24,
      "start_time": 107094.0,
      "end_time": 112101.0,
      "text": "pumps, the volume occupied by blood varies during the pumping cycle, and if"
    },
    {
      "index": 25,
      "start_time": 112101.0,
      "end_time": 117175.0,
      "text": "the pump is contained inside the body then a vent tube to the outside air is"
    },
    {
      "index": 26,
      "start_time": 117175.0,
      "end_time": 120219.0,
      "text": "required. Continuous flow VADs are smaller and"
    },
    {
      "index": 27,
      "start_time": 120219.0,
      "end_time": 125293.0,
      "text": "have proven to be more durable than pulsatile VADs. They normally use either"
    },
    {
      "index": 28,
      "start_time": 125293.0,
      "end_time": 130164.0,
      "text": "a centrifugal pump or an axial flow pump. Both types have a central rotor"
    },
    {
      "index": 29,
      "start_time": 130163.99999999999,
      "end_time": 135509.0,
      "text": "containing permanent magnets. Controlled electric currents running through coils"
    },
    {
      "index": 30,
      "start_time": 135509.0,
      "end_time": 140312.0,
      "text": "contained in the pump housing apply forces to the magnets, which in turn"
    },
    {
      "index": 31,
      "start_time": 140312.0,
      "end_time": 145183.0,
      "text": "cause the rotors to spin. In the centrifugal pumps, the rotors are shaped"
    },
    {
      "index": 32,
      "start_time": 145183.0,
      "end_time": 149310.0,
      "text": "to accelerate the blood circumferentially and thereby cause it"
    },
    {
      "index": 33,
      "start_time": 149310.0,
      "end_time": 154181.0,
      "text": "to move toward the outer rim of the pump, whereas in the axial flow pumps"
    },
    {
      "index": 34,
      "start_time": 154181.0,
      "end_time": 159323.0,
      "text": "the rotors are more or less cylindrical with blades that are helical, causing"
    },
    {
      "index": 35,
      "start_time": 159323.0,
      "end_time": 163652.0,
      "text": "the blood to be accelerated in the direction of the rotor&#39;s axis."
    },
    {
      "index": 36,
      "start_time": 163652.0,
      "end_time": 168929.0,
      "text": "An important issue with continuous flow pumps is the method used to suspend the"
    },
    {
      "index": 37,
      "start_time": 168929.0,
      "end_time": 173733.0,
      "text": "rotor. Early versions used solid bearings; however, newer pumps, some of"
    },
    {
      "index": 38,
      "start_time": 173733.0,
      "end_time": 178942.0,
      "text": "which are approved for use in the EU, use either electromagnetic suspension or"
    },
    {
      "index": 39,
      "start_time": 178942.0,
      "end_time": 183339.0,
      "text": "hydrodynamic suspension. These pumps contain only one moving part."
    },
    {
      "index": 40,
      "start_time": 183339.0,
      "end_time": 186384.0,
      "text": "History The first successful implantation of a"
    },
    {
      "index": 41,
      "start_time": 186384.0,
      "end_time": 191052.0,
      "text": "left ventricular assist device was completed in 1966 by Dr. Michael E."
    },
    {
      "index": 42,
      "start_time": 191052.0,
      "end_time": 195517.0,
      "text": "DeBakey to a 37-year-old woman. A paracorporeal circuit was able to"
    },
    {
      "index": 43,
      "start_time": 195517.0,
      "end_time": 200726.0,
      "text": "provide mechanical support for 10 days after the surgery. The first successful"
    },
    {
      "index": 44,
      "start_time": 200726.0,
      "end_time": 205597.0,
      "text": "long-term implantation of an artificial LVAD was conducted in 1988 by Dr."
    },
    {
      "index": 45,
      "start_time": 205597.0,
      "end_time": 210942.0,
      "text": "William F. Bernhard of Boston Children&#39;s Hospital Medical Center and Thermedics,"
    },
    {
      "index": 46,
      "start_time": 210942.0,
      "end_time": 215813.0,
      "text": "Inc of Woburn, MA under a National Institutes of Health research contract"
    },
    {
      "index": 47,
      "start_time": 215813.0,
      "end_time": 220549.0,
      "text": "which developed Heart-mate, an electronically controlled assist device."
    },
    {
      "index": 48,
      "start_time": 220549.0,
      "end_time": 225284.0,
      "text": "This was funded by a three year $6.2 million contract to Thermedics and"
    },
    {
      "index": 49,
      "start_time": 225284.0,
      "end_time": 230155.0,
      "text": "Children&#39;s Hospital, Boston MA from the National Heart and Lung and Blood"
    },
    {
      "index": 50,
      "start_time": 230155.0,
      "end_time": 235026.0,
      "text": "Institute, a program of NIH. The early VADs emulated the heart by using a"
    },
    {
      "index": 51,
      "start_time": 235026.0,
      "end_time": 239762.0,
      "text": "&quot;pulsatile&quot; action where blood is alternately sucked into the pump from"
    },
    {
      "index": 52,
      "start_time": 239762.0,
      "end_time": 245039.0,
      "text": "the left ventricle then forced out into the aorta. Devices of this kind include"
    },
    {
      "index": 53,
      "start_time": 245039.0,
      "end_time": 249775.0,
      "text": "the HeartMate IP LVAS, which was approved for use in the US by the Food"
    },
    {
      "index": 54,
      "start_time": 249775.0,
      "end_time": 255052.0,
      "text": "and Drug Administration in October 1994. These devices are commonly referred to"
    },
    {
      "index": 55,
      "start_time": 255052.0,
      "end_time": 259179.0,
      "text": "as first generation VADs. More recent work has concentrated on"
    },
    {
      "index": 56,
      "start_time": 259178.99999999997,
      "end_time": 263508.0,
      "text": "continuous flow pumps, which can be roughly categorized as either"
    },
    {
      "index": 57,
      "start_time": 263508.0,
      "end_time": 268515.0,
      "text": "centrifugal pumps or axial flow impeller driven pumps. These pumps have the"
    },
    {
      "index": 58,
      "start_time": 268515.0,
      "end_time": 273115.0,
      "text": "advantage of greater simplicity resulting in smaller size and greater"
    },
    {
      "index": 59,
      "start_time": 273115.0,
      "end_time": 278189.0,
      "text": "reliability. These devices are referred to as second generation VADs. A side"
    },
    {
      "index": 60,
      "start_time": 278189.0,
      "end_time": 283466.0,
      "text": "effect is that the user will not have a pulse, or that the pulse intensity will"
    },
    {
      "index": 61,
      "start_time": 283466.0,
      "end_time": 287119.0,
      "text": "be seriously reduced. Third generation VADs suspend the"
    },
    {
      "index": 62,
      "start_time": 287119.0,
      "end_time": 291449.0,
      "text": "impeller in the pump using either hydrodynamic or electromagnetic"
    },
    {
      "index": 63,
      "start_time": 291449.0,
      "end_time": 296388.0,
      "text": "suspension, thus removing the need for bearings and reducing the number of"
    },
    {
      "index": 64,
      "start_time": 296388.0,
      "end_time": 300312.0,
      "text": "moving parts to one. Another technology undergoing clinical"
    },
    {
      "index": 65,
      "start_time": 300312.0,
      "end_time": 305047.0,
      "text": "trials is the use of trans cutaneous induction to power and control the"
    },
    {
      "index": 66,
      "start_time": 305047.0,
      "end_time": 310189.0,
      "text": "device rather than using percutaneous cables. Apart from the obvious cosmetic"
    },
    {
      "index": 67,
      "start_time": 310189.0,
      "end_time": 314925.0,
      "text": "advantage this reduces the risk of infection and the consequent need to"
    },
    {
      "index": 68,
      "start_time": 314925.0,
      "end_time": 319999.0,
      "text": "take preventative action. A pulsatile pump using this technology has CE Mark"
    },
    {
      "index": 69,
      "start_time": 319999.0,
      "end_time": 323652.0,
      "text": "approval and is in clinical trials for US FDA approval."
    },
    {
      "index": 70,
      "start_time": 323652.0,
      "end_time": 328794.0,
      "text": "A very different approach in the early stages of development is the use of an"
    },
    {
      "index": 71,
      "start_time": 328794.0,
      "end_time": 333597.0,
      "text": "inflatable cuff around the aorta. Inflating the cuff contracts the aorta"
    },
    {
      "index": 72,
      "start_time": 333597.0,
      "end_time": 338874.0,
      "text": "and deflating the cuff allows the aorta to expand – in effect the aorta becomes"
    },
    {
      "index": 73,
      "start_time": 338874.0,
      "end_time": 343542.0,
      "text": "a second left ventricle. A proposed refinement is to use the patient&#39;s"
    },
    {
      "index": 74,
      "start_time": 343542.0,
      "end_time": 348887.0,
      "text": "skeletal muscle, driven by a pacemaker, to power this device which would make it"
    },
    {
      "index": 75,
      "start_time": 348887.0,
      "end_time": 354028.0,
      "text": "truly self-contained. However a similar operation was tried in the 1990s with"
    },
    {
      "index": 76,
      "start_time": 354028.0,
      "end_time": 359238.0,
      "text": "disappointing results. In any case, it has substantial potential advantages in"
    },
    {
      "index": 77,
      "start_time": 359238.0,
      "end_time": 364312.0,
      "text": "avoiding the need to operate on the heart itself and in avoiding any contact"
    },
    {
      "index": 78,
      "start_time": 364312.0,
      "end_time": 368709.0,
      "text": "between blood and the device. This approach involves a return to a"
    },
    {
      "index": 79,
      "start_time": 368709.0,
      "end_time": 372430.0,
      "text": "pulsatile flow. Peter Houghton was the longest surviving"
    },
    {
      "index": 80,
      "start_time": 372430.0,
      "end_time": 377572.0,
      "text": "recipient of a VAD for permanent use. He received an experimental Jarvik 2000"
    },
    {
      "index": 81,
      "start_time": 377572.0,
      "end_time": 382037.0,
      "text": "LVAD in June 2000. Since then, he completed a 91-mile charity walk,"
    },
    {
      "index": 82,
      "start_time": 382037.0,
      "end_time": 387246.0,
      "text": "published two books, lectured widely, hiked in the Swiss Alps and the American"
    },
    {
      "index": 83,
      "start_time": 387246.0,
      "end_time": 392185.0,
      "text": "West, flew in an ultra-light aircraft, and traveled extensively around the"
    },
    {
      "index": 84,
      "start_time": 392185.0,
      "end_time": 396379.0,
      "text": "world. He died of acute renal failure in 2007 at the age of 69."
    },
    {
      "index": 85,
      "start_time": 396379.0,
      "end_time": 399221.0,
      "text": "Studies and outcomes = Recent developments="
    },
    {
      "index": 86,
      "start_time": 399221.0,
      "end_time": 403821.0,
      "text": "In July 2009 in England, surgeons removed a donor heart that had been"
    },
    {
      "index": 87,
      "start_time": 403821.0,
      "end_time": 408827.0,
      "text": "implanted in a toddler next to her native heart, after her native heart had"
    },
    {
      "index": 88,
      "start_time": 408827.0,
      "end_time": 413563.0,
      "text": "recovered. This technique suggests mechanical assist device, such as an"
    },
    {
      "index": 89,
      "start_time": 413563.0,
      "end_time": 418908.0,
      "text": "LVAD, can take some or all the work away from the native heart and allow it time"
    },
    {
      "index": 90,
      "start_time": 418908.0,
      "end_time": 422155.0,
      "text": "to heal. In July 2009, 18-month follow-up results"
    },
    {
      "index": 91,
      "start_time": 422155.0,
      "end_time": 426958.0,
      "text": "from the HeartMate II Clinical Trial concluded that continuous-flow LVAD"
    },
    {
      "index": 92,
      "start_time": 426958.0,
      "end_time": 431829.0,
      "text": "provides effective hemodynamic support for at least 18 months in patients"
    },
    {
      "index": 93,
      "start_time": 431829.0,
      "end_time": 437106.0,
      "text": "awaiting transplantation, with improved functional status and quality of life.."
    },
    {
      "index": 94,
      "start_time": 437106.0,
      "end_time": 441571.0,
      "text": "Heidelberg University Hospital reported in July 2009 that the first"
    },
    {
      "index": 95,
      "start_time": 441571.0,
      "end_time": 445901.0,
      "text": "HeartAssist5, known as the modern version of the DeBakey VAD, was"
    },
    {
      "index": 96,
      "start_time": 445901.0,
      "end_time": 450840.0,
      "text": "implanted there. The HeartAssist5 weighs 92 grams, is made of titanium and"
    },
    {
      "index": 97,
      "start_time": 450840.0,
      "end_time": 455711.0,
      "text": "plastic, and serves to pump blood from the left ventricle into the aorta."
    },
    {
      "index": 98,
      "start_time": 455711.0,
      "end_time": 460650.0,
      "text": "A phase 1 clinical trial is underway, consisting of patients with coronary"
    },
    {
      "index": 99,
      "start_time": 460650.0,
      "end_time": 465859.0,
      "text": "artery bypass grafting and patients in end-stage heart failure who have a left"
    },
    {
      "index": 100,
      "start_time": 465859.0,
      "end_time": 470459.0,
      "text": "ventricular assist device. The trial involves testing a patch, called"
    },
    {
      "index": 101,
      "start_time": 470459.0,
      "end_time": 475669.0,
      "text": "Anginera(TM) that contains cells that secrete hormone-like growth factors that"
    },
    {
      "index": 102,
      "start_time": 475669.0,
      "end_time": 480404.0,
      "text": "stimulate other cells to grow. The patches are seeded with heart muscle"
    },
    {
      "index": 103,
      "start_time": 480404.0,
      "end_time": 485411.0,
      "text": "cells and then implanted onto the heart with the goal of getting the muscle"
    },
    {
      "index": 104,
      "start_time": 485411.0,
      "end_time": 490823.0,
      "text": "cells to start communicating with native tissues in a way that allows for regular"
    },
    {
      "index": 105,
      "start_time": 490823.0,
      "end_time": 494206.0,
      "text": "contractions. In September 2009, a New Zealand news"
    },
    {
      "index": 106,
      "start_time": 494206.0,
      "end_time": 499415.0,
      "text": "outlet, Stuff, reported that in another 18 months to two years, a new wireless"
    },
    {
      "index": 107,
      "start_time": 499415.0,
      "end_time": 504421.0,
      "text": "device will be ready for clinical trial that will power VADs without direct"
    },
    {
      "index": 108,
      "start_time": 504421.0,
      "end_time": 509631.0,
      "text": "contact. If successful, this may reduce the chance of infection as a result of"
    },
    {
      "index": 109,
      "start_time": 509631.0,
      "end_time": 514096.0,
      "text": "the power cable through the skin. The National Institutes of Health"
    },
    {
      "index": 110,
      "start_time": 514096.0,
      "end_time": 519237.0,
      "text": "awarded a $2.8 million grant to develop a &quot;pulse-less&quot; total artificial heart"
    },
    {
      "index": 111,
      "start_time": 519236.99999999994,
      "end_time": 524243.99999999994,
      "text": "using two VADS by Micromed, initially created by Michael DeBakey and George"
    },
    {
      "index": 112,
      "start_time": 524244.0,
      "end_time": 529385.0,
      "text": "Noon. The grant was renewed for a second year of research in August 2009. The"
    },
    {
      "index": 113,
      "start_time": 529385.0,
      "end_time": 534662.0,
      "text": "Total Artificial Heart was created using two HeartAssist5 VADs, whereby one VAD"
    },
    {
      "index": 114,
      "start_time": 534662.0,
      "end_time": 539871.0,
      "text": "pumps blood throughout the body and the other circulates blood to and from the"
    },
    {
      "index": 115,
      "start_time": 539871.0,
      "end_time": 542713.0,
      "text": "lungs. HeartWare International announced in"
    },
    {
      "index": 116,
      "start_time": 542713.0,
      "end_time": 547787.0,
      "text": "August 2009 that it had surpassed 50 implants of their HeartWare Ventricular"
    },
    {
      "index": 117,
      "start_time": 547787.0,
      "end_time": 552929.0,
      "text": "Assist System in their ADVANCE Clinical Trial, an FDA-approved IDE study. The"
    },
    {
      "index": 118,
      "start_time": 552929.0,
      "end_time": 557529.0,
      "text": "study is to assess the system as bridge-to-transplantation system for"
    },
    {
      "index": 119,
      "start_time": 557529.0,
      "end_time": 562671.0,
      "text": "patients with end-stage heart failure. The study, Evaluation of the HeartWare"
    },
    {
      "index": 120,
      "start_time": 562671.0,
      "end_time": 567948.0,
      "text": "LVAD System for the Treatment of Advance Heart Failure, is a multi-center study"
    },
    {
      "index": 121,
      "start_time": 567948.0,
      "end_time": 572345.0,
      "text": "that started in May 2009. On June 27, 2014 Hannover Medical School"
    },
    {
      "index": 122,
      "start_time": 572345.0,
      "end_time": 577757.0,
      "text": "in Hannover, Germany performed the first human implant of HeartMate III under the"
    },
    {
      "index": 123,
      "start_time": 577757.0,
      "end_time": 582493.0,
      "text": "direction of Professor Axel Haverich M.D., chief of the Cardiothoracic,"
    },
    {
      "index": 124,
      "start_time": 582493.0,
      "end_time": 587364.0,
      "text": "Transplantation and Vascular Surgery Department and surgeon Jan Schmitto,"
    },
    {
      "index": 125,
      "start_time": 587364.0,
      "end_time": 590205.0,
      "text": "M.D., Ph.D. On January 21, 2015 a study was"
    },
    {
      "index": 126,
      "start_time": 590205.0,
      "end_time": 595550.0,
      "text": "published in Journal of American College of Cardiology suggesting that long-term"
    },
    {
      "index": 127,
      "start_time": 595550.0,
      "end_time": 599745.0,
      "text": "use of LVAD may induce heart regeneration. This may explain the"
    },
    {
      "index": 128,
      "start_time": 599745.0,
      "end_time": 604818.0,
      "text": "bridge to recovery phenomenon first described by the Yacoub group in NEJM in"
    },
    {
      "index": 129,
      "start_time": 604818.0,
      "end_time": 607863.0,
      "text": "2009. The majority of VADs on the market today"
    },
    {
      "index": 130,
      "start_time": 607863.0,
      "end_time": 613072.0,
      "text": "are somewhat bulky. The smallest device approved by the FDA, the HeartMate II,"
    },
    {
      "index": 131,
      "start_time": 613072.0,
      "end_time": 617876.0,
      "text": "weighs about 1 pound and measures 3 inches. This has proven particularly"
    },
    {
      "index": 132,
      "start_time": 617876.0,
      "end_time": 622882.0,
      "text": "important for women and children, for whom alternatives would have been too"
    },
    {
      "index": 133,
      "start_time": 622882.0,
      "end_time": 625859.0,
      "text": "large. One device gained CE Mark approval for"
    },
    {
      "index": 134,
      "start_time": 625859.0,
      "end_time": 631068.0,
      "text": "use in the EU and began clinical trials in the US. As of June 2007 these pumps"
    },
    {
      "index": 135,
      "start_time": 631068.0,
      "end_time": 636345.0,
      "text": "had been implanted in over 100 patients. In 2009, Ventracor was placed into the"
    },
    {
      "index": 136,
      "start_time": 636345.0,
      "end_time": 641216.0,
      "text": "hands of Administrators due to financial problems and was later that year"
    },
    {
      "index": 137,
      "start_time": 641216.0,
      "end_time": 646222.0,
      "text": "liquidated. No other companies purchased the technology, so as a result the"
    },
    {
      "index": 138,
      "start_time": 646222.0,
      "end_time": 651229.0,
      "text": "VentrAssist device was essentially defunct. Around 30–50 patients worldwide"
    },
    {
      "index": 139,
      "start_time": 651229.0,
      "end_time": 655152.0,
      "text": "remain supported on VentrAssist devices as of January 2010."
    },
    {
      "index": 140,
      "start_time": 655152.0,
      "end_time": 660159.0,
      "text": "The Heartware HVAD works similarly to the VentrAssist – albeit much smaller"
    },
    {
      "index": 141,
      "start_time": 660159.0,
      "end_time": 665097.0,
      "text": "and not requiring an abdominal pocket to be implanted into. The device has"
    },
    {
      "index": 142,
      "start_time": 665097.0,
      "end_time": 669968.0,
      "text": "obtained CE Mark in Europe, and FDA approval in the U.S. Recently, it was"
    },
    {
      "index": 143,
      "start_time": 669968.0,
      "end_time": 675110.0,
      "text": "shown that the Heartware HVAD can be implanted through limited access without"
    },
    {
      "index": 144,
      "start_time": 675110.0,
      "end_time": 677952.0,
      "text": "sternotomy. In a small number of cases left"
    },
    {
      "index": 145,
      "start_time": 677952.0,
      "end_time": 682755.0,
      "text": "ventricular assist devices, combined with drug therapy, have enabled the"
    },
    {
      "index": 146,
      "start_time": 682755.0,
      "end_time": 687423.0,
      "text": "heart to recover sufficiently for the device to be able to be removed."
    },
    {
      "index": 147,
      "start_time": 687423.0,
      "end_time": 692429.0,
      "text": "= HeartMate II LVAD pivotal study= A series of studies involving the use of"
    },
    {
      "index": 148,
      "start_time": 692429.0,
      "end_time": 697571.0,
      "text": "the of HeartMate II LVAD have proven useful in establishing the viability and"
    },
    {
      "index": 149,
      "start_time": 697571.0,
      "end_time": 701157.0,
      "text": "risks of using LVADs for bridge-to-transplantation and"
    },
    {
      "index": 150,
      "start_time": 701157.0,
      "end_time": 704945.0,
      "text": "destination therapy. The pilot trial for the HeartMate II"
    },
    {
      "index": 151,
      "start_time": 704945.0,
      "end_time": 709478.0,
      "text": "LVAS began in November 2003 and consisted of 46 study patients at 15"
    },
    {
      "index": 152,
      "start_time": 709478.0,
      "end_time": 714417.0,
      "text": "centers. Results included 11 patients supported for more than one year and"
    },
    {
      "index": 153,
      "start_time": 714417.0,
      "end_time": 717664.0,
      "text": "three patients supported for more than two years."
    },
    {
      "index": 154,
      "start_time": 717664.0,
      "end_time": 722670.0,
      "text": "The HeartMate II pivotal trial began in 2005 and included the evaluation of"
    },
    {
      "index": 155,
      "start_time": 722670.0,
      "end_time": 727677.0,
      "text": "HeartMate II for two indications: Bridge to transplantation and destination"
    },
    {
      "index": 156,
      "start_time": 727677.0,
      "end_time": 732412.0,
      "text": "therapy, or long-term, permanent support. Thoratec Corp. announced that"
    },
    {
      "index": 157,
      "start_time": 732412.0,
      "end_time": 737216.0,
      "text": "this was the first time the FDA had approved a clinical trial to include"
    },
    {
      "index": 158,
      "start_time": 737216.0,
      "end_time": 742154.0,
      "text": "both indications in one protocol. A multicenter study in the United States"
    },
    {
      "index": 159,
      "start_time": 742154.0,
      "end_time": 747161.0,
      "text": "from 2005 to 2007 with 113 patients showed that significant improvements in"
    },
    {
      "index": 160,
      "start_time": 747161.0,
      "end_time": 752235.0,
      "text": "function were prevalent after three months, and a survival rate of 68% after"
    },
    {
      "index": 161,
      "start_time": 752235.0,
      "end_time": 755685.0,
      "text": "twelve months. Based on one-year follow up data from"
    },
    {
      "index": 162,
      "start_time": 755685.0,
      "end_time": 760962.0,
      "text": "the first 194 patients enrolled in the trial, the FDA approved HeartMate II for"
    },
    {
      "index": 163,
      "start_time": 760962.0,
      "end_time": 765968.0,
      "text": "bridge-to-transplantation. The trial provided clinical evidence of improved"
    },
    {
      "index": 164,
      "start_time": 765968.0,
      "end_time": 770298.0,
      "text": "survival rates and quality of life for a broad range of patients."
    },
    {
      "index": 165,
      "start_time": 770298.0,
      "end_time": 775101.0,
      "text": "Eighteen-month follow up data on 281 patients who had either reached the"
    },
    {
      "index": 166,
      "start_time": 775101.0,
      "end_time": 779972.0,
      "text": "study end-point or completed 18 months of post-operative follow-up showed"
    },
    {
      "index": 167,
      "start_time": 779972.0,
      "end_time": 785046.0,
      "text": "improved survival, less frequent adverse events and greater reliability with"
    },
    {
      "index": 168,
      "start_time": 785046.0,
      "end_time": 789579.0,
      "text": "continuous flow LVADS compared to pulsatile flow devices. Of the 281"
    },
    {
      "index": 169,
      "start_time": 789579.0,
      "end_time": 794653.0,
      "text": "patients, 157 patients had undergone transplant, 58 patients were continuing"
    },
    {
      "index": 170,
      "start_time": 794653.0,
      "end_time": 799457.0,
      "text": "with LVADs in their body and seven patients had the LVAD removed because"
    },
    {
      "index": 171,
      "start_time": 799457.0,
      "end_time": 804598.0,
      "text": "their heart recovered; the remaining 56 had died. The results showed that the"
    },
    {
      "index": 172,
      "start_time": 804598.0,
      "end_time": 809807.0,
      "text": "NYHA Class of heart failure the patients had been designated had significantly"
    },
    {
      "index": 173,
      "start_time": 809807.0,
      "end_time": 814205.0,
      "text": "improved after six months of LVAD support compared to the pre-LVAD"
    },
    {
      "index": 174,
      "start_time": 814205.0,
      "end_time": 819211.0,
      "text": "baseline. Although this trial involved bridge-to-transplant indication, the"
    },
    {
      "index": 175,
      "start_time": 819211.0,
      "end_time": 824285.0,
      "text": "results provide early evidence that continuous flow LVADs have advantages in"
    },
    {
      "index": 176,
      "start_time": 824285.0,
      "end_time": 829427.0,
      "text": "terms of durability and reliability for patients receiving mechanical support"
    },
    {
      "index": 177,
      "start_time": 829427.0,
      "end_time": 833689.0,
      "text": "for destination therapy. Following the FDA approval of HeartMate"
    },
    {
      "index": 178,
      "start_time": 833689.0,
      "end_time": 838560.0,
      "text": "II LVAD for bridge-to-transplantation purposes, a post-approval study was"
    },
    {
      "index": 179,
      "start_time": 838560.0,
      "end_time": 843634.0,
      "text": "undertaken to assess the efficacy of the device in a commercial setting. The"
    },
    {
      "index": 180,
      "start_time": 843634.0,
      "end_time": 848573.0,
      "text": "study found that the device improved outcomes, both compared to other LVAD"
    },
    {
      "index": 181,
      "start_time": 848573.0,
      "end_time": 853173.0,
      "text": "treatments and baseline patients. Specifically, HeartMate II patients"
    },
    {
      "index": 182,
      "start_time": 853173.0,
      "end_time": 858382.0,
      "text": "showed lower creatinine levels, 30-day survival rates were considerably higher"
    },
    {
      "index": 183,
      "start_time": 858382.0,
      "end_time": 861292.0,
      "text": "at 96%, and 93% reached successful outcomes."
    },
    {
      "index": 184,
      "start_time": 861292.0,
      "end_time": 864539.0,
      "text": "= HARPS= The Harefield Recovery Protocol Study is"
    },
    {
      "index": 185,
      "start_time": 864539.0,
      "end_time": 869072.0,
      "text": "a clinical trial to evaluate whether advanced heart failure patients"
    },
    {
      "index": 186,
      "start_time": 869072.0,
      "end_time": 873943.0,
      "text": "requiring VAD support can recover sufficient myocardial function to allow"
    },
    {
      "index": 187,
      "start_time": 873943.0,
      "end_time": 878949.0,
      "text": "device removal. HARPS combines an LVAD with conventional oral heart failure"
    },
    {
      "index": 188,
      "start_time": 878949.0,
      "end_time": 883820.0,
      "text": "medications, followed by the novel β2 agonist clenbuterol. This opens the"
    },
    {
      "index": 189,
      "start_time": 883820.0,
      "end_time": 888420.0,
      "text": "possibility that some advanced heart failure patients may forgo heart"
    },
    {
      "index": 190,
      "start_time": 888420.0,
      "end_time": 892074.0,
      "text": "transplantation. To date, 73% of patients who underwent"
    },
    {
      "index": 191,
      "start_time": 892074.0,
      "end_time": 896539.0,
      "text": "the combination therapy regimen demonstrated sufficient recovery to"
    },
    {
      "index": 192,
      "start_time": 896539.0,
      "end_time": 901477.0,
      "text": "allow explantation and avoid heart transplantation; freedom from recurrent"
    },
    {
      "index": 193,
      "start_time": 901477.0,
      "end_time": 906822.0,
      "text": "heart failure in surviving patients was 100% and 89% at one and four years after"
    },
    {
      "index": 194,
      "start_time": 906822.0,
      "end_time": 911761.0,
      "text": "explantation, respectively; average ejection fraction was 64% at 59 months"
    },
    {
      "index": 195,
      "start_time": 911761.0,
      "end_time": 917038.0,
      "text": "after explantation – all patients were NYHA Class I; and no significant adverse"
    },
    {
      "index": 196,
      "start_time": 917038.0,
      "end_time": 920150.0,
      "text": "effects were reported with clenbuterol therapy."
    },
    {
      "index": 197,
      "start_time": 920150.0,
      "end_time": 923465.0,
      "text": "= REMATCH= The REMATCH clinical trial began in May"
    },
    {
      "index": 198,
      "start_time": 923465.0,
      "end_time": 928403.0,
      "text": "1998 and ran through July 2001 in 20 cardiac transplant centers around the"
    },
    {
      "index": 199,
      "start_time": 928403.0,
      "end_time": 933004.0,
      "text": "USA. The trial was designed to compare long-term implantation of left"
    },
    {
      "index": 200,
      "start_time": 933004.0,
      "end_time": 938078.0,
      "text": "ventricular assist devices with optimal medical management for patients with"
    },
    {
      "index": 201,
      "start_time": 938078.0,
      "end_time": 943016.0,
      "text": "end-stage heart failure who require, but do not qualify to receive cardiac"
    },
    {
      "index": 202,
      "start_time": 943016.0,
      "end_time": 947955.0,
      "text": "transplantation. As a result of the clinical outcomes, the device received"
    },
    {
      "index": 203,
      "start_time": 947955.0,
      "end_time": 952353.0,
      "text": "FDA approval for both indications, in 2001 and 2003, respectively."
    },
    {
      "index": 204,
      "start_time": 952353.0,
      "end_time": 956885.0,
      "text": "The trial demonstrated an 81% improvement in two-year survival among"
    },
    {
      "index": 205,
      "start_time": 956885.0,
      "end_time": 961689.0,
      "text": "patients receiving HeartMate XVE compared to optimal medical management."
    },
    {
      "index": 206,
      "start_time": 961689.0,
      "end_time": 967101.0,
      "text": "In addition, a destination therapy study following the REMATCH trial demonstrated"
    },
    {
      "index": 207,
      "start_time": 967101.0,
      "end_time": 971904.0,
      "text": "an additional 17% improvement in one-year survival of patients that were"
    },
    {
      "index": 208,
      "start_time": 971904.0,
      "end_time": 975964.0,
      "text": "implanted with a VAD, with an implication for the appropriate"
    },
    {
      "index": 209,
      "start_time": 975964.0,
      "end_time": 979617.0,
      "text": "selection of candidates and timing of VAD implantation."
    },
    {
      "index": 210,
      "start_time": 979617.0,
      "end_time": 984623.0,
      "text": "A test carried out in 2001 by Dr. Eric A. Rose and REMATCH study group with"
    },
    {
      "index": 211,
      "start_time": 984623.0,
      "end_time": 989697.0,
      "text": "patients with congestive heart failure that were ineligible for a transplant"
    },
    {
      "index": 212,
      "start_time": 989697.0,
      "end_time": 994365.0,
      "text": "showed a survival at two years of 23% for those implanted with an LVAD"
    },
    {
      "index": 213,
      "start_time": 994365.0,
      "end_time": 998966.0,
      "text": "compared with 8% for those who were treated with drugs. The two major"
    },
    {
      "index": 214,
      "start_time": 998966.0,
      "end_time": 1003769.0,
      "text": "complications of VAD implantation were infection and mechanical failure."
    },
    {
      "index": 215,
      "start_time": 1003770.0,
      "end_time": 1008776.0,
      "text": "According to a retrospective cohort study comparing patients treated with a"
    },
    {
      "index": 216,
      "start_time": 1008780.0,
      "end_time": 1013787.0,
      "text": "left ventricular assist device versus inotrope therapy while awaiting heart"
    },
    {
      "index": 217,
      "start_time": 1013780.0,
      "end_time": 1019124.0,
      "text": "transplantation, the group treated with LVAD had improved clinical and metabolic"
    },
    {
      "index": 218,
      "start_time": 1019130.0,
      "end_time": 1024204.0,
      "text": "function at the time of transplant with better blood pressure, sodium, blood"
    },
    {
      "index": 219,
      "start_time": 1024200.0,
      "end_time": 1029274.0,
      "text": "urea nitrogen, and creatinine. After transplant, 57.7% of the inotrope group"
    },
    {
      "index": 220,
      "start_time": 1029270.0,
      "end_time": 1034412.0,
      "text": "had renal failure versus 16.6% in the LVAD group; 31.6% of the inotrope group"
    },
    {
      "index": 221,
      "start_time": 1034420.0000000001,
      "end_time": 1039629.0000000001,
      "text": "had right heart failure versus 5.6% in the LVAD group; and event-free survival"
    },
    {
      "index": 222,
      "start_time": 1039619.9999999999,
      "end_time": 1043814.9999999999,
      "text": "was 15.8% in the inotrope group versus 55.6% in the LVAD group."
    },
    {
      "index": 223,
      "start_time": 1043819.9999999999,
      "end_time": 1047675.9999999999,
      "text": "Complications and side effects Bleeding is the most common"
    },
    {
      "index": 224,
      "start_time": 1047680.0000000001,
      "end_time": 1052822.0,
      "text": "postoperative early complication after implantation or explantation of LVADs,"
    },
    {
      "index": 225,
      "start_time": 1052820.0,
      "end_time": 1057691.0,
      "text": "necessitating reoperation in up to 60% of recipients. The implications of"
    },
    {
      "index": 226,
      "start_time": 1057690.0,
      "end_time": 1062290.0,
      "text": "massive blood transfusions are great and include infection, pulmonary"
    },
    {
      "index": 227,
      "start_time": 1062290.0,
      "end_time": 1067296.0,
      "text": "insufficiency, increased costs, right heart failure, allosensitization, and"
    },
    {
      "index": 228,
      "start_time": 1067300.0,
      "end_time": 1072510.0,
      "text": "viral transmission, some of which can prove fatal or preclude transplantation."
    },
    {
      "index": 229,
      "start_time": 1072510.0,
      "end_time": 1077922.0,
      "text": "When bleeding occurs, it impacts the one year Kaplan-Meier mortality. In addition"
    },
    {
      "index": 230,
      "start_time": 1077920.0,
      "end_time": 1083129.0,
      "text": "to complexity of the patient population and the complexity of these procedures"
    },
    {
      "index": 231,
      "start_time": 1083130.0,
      "end_time": 1088272.0,
      "text": "contributing to bleeding, the devices themselves may contribute to the severe"
    },
    {
      "index": 232,
      "start_time": 1088270.0,
      "end_time": 1093411.0,
      "text": "coagulopathy that can ensue when these devices are implanted. Critical in the"
    },
    {
      "index": 233,
      "start_time": 1093410.0,
      "end_time": 1098484.0,
      "text": "management of bleeding in the early hours after implantation or explantation"
    },
    {
      "index": 234,
      "start_time": 1098480.0,
      "end_time": 1102810.0,
      "text": "is to adequately evacuate the post-surgical blood from around the"
    },
    {
      "index": 235,
      "start_time": 1102810.0,
      "end_time": 1107817.0,
      "text": "heart and lungs to prevent retained blood from contributing to the need for"
    },
    {
      "index": 236,
      "start_time": 1107820.0,
      "end_time": 1112488.0,
      "text": "reoperation to wash out clot that can compress the device features and"
    },
    {
      "index": 237,
      "start_time": 1112490.0,
      "end_time": 1117361.0,
      "text": "contribute to post operative shock. Preventing chest tube clogging during"
    },
    {
      "index": 238,
      "start_time": 1117360.0,
      "end_time": 1122434.0,
      "text": "this period is critical to recovery. Because the devices generally result in"
    },
    {
      "index": 239,
      "start_time": 1122430.0,
      "end_time": 1126962.0,
      "text": "blood flowing over a non-biologic surface, predisposing the blood to"
    },
    {
      "index": 240,
      "start_time": 1126960.0,
      "end_time": 1131290.0,
      "text": "clotting, there is need for anticoagulation measures. One device,"
    },
    {
      "index": 241,
      "start_time": 1131300.0,
      "end_time": 1136509.0,
      "text": "the HeartMate XVE, is designed with a biologic surface derived from fibrin and"
    },
    {
      "index": 242,
      "start_time": 1136500.0,
      "end_time": 1140695.0,
      "text": "does not require long term anticoagulation; unfortunately, this"
    },
    {
      "index": 243,
      "start_time": 1140700.0,
      "end_time": 1145977.0,
      "text": "biologic surface may also predispose the patient to infection through selective"
    },
    {
      "index": 244,
      "start_time": 1145980.0,
      "end_time": 1148686.0,
      "text": "reduction of certain types of leukocytes."
    },
    {
      "index": 245,
      "start_time": 1148680.0,
      "end_time": 1153754.0,
      "text": "New VAD designs which are now approved for use in the European Community and"
    },
    {
      "index": 246,
      "start_time": 1153760.0,
      "end_time": 1158631.0,
      "text": "are undergoing trials for FDA approval have all but eliminated mechanical"
    },
    {
      "index": 247,
      "start_time": 1158630.0,
      "end_time": 1161877.0,
      "text": "failure. VAD-related infection can be caused by a"
    },
    {
      "index": 248,
      "start_time": 1161870.0,
      "end_time": 1165794.0,
      "text": "large number of different organisms: Gram positive bacteria"
    },
    {
      "index": 249,
      "start_time": 1165800.0,
      "end_time": 1169521.0,
      "text": "Gram negative bacteria Fungi. especially Candida species"
    },
    {
      "index": 250,
      "start_time": 1169520.0,
      "end_time": 1174662.0,
      "text": "Treatment of VAD-related infection is exceedingly difficult and many patients"
    },
    {
      "index": 251,
      "start_time": 1174660.0,
      "end_time": 1179396.0,
      "text": "die of infection despite optimal treatment. Initial treatment should be"
    },
    {
      "index": 252,
      "start_time": 1179400.0,
      "end_time": 1184203.0,
      "text": "with broad spectrum antibiotics, but every effort must be made to obtain"
    },
    {
      "index": 253,
      "start_time": 1184200.0,
      "end_time": 1189409.0,
      "text": "appropriate samples for culture. A final decision regarding antibiotic therapy"
    },
    {
      "index": 254,
      "start_time": 1189410.0,
      "end_time": 1193063.0,
      "text": "must be based on the results of microbiogical cultures."
    },
    {
      "index": 255,
      "start_time": 1193060.0,
      "end_time": 1196714.0,
      "text": "Other problems include immunosuppression, clotting with"
    },
    {
      "index": 256,
      "start_time": 1196720.0,
      "end_time": 1201523.0,
      "text": "resultant stroke, and bleeding secondary to anticoagulation. Some of the"
    },
    {
      "index": 257,
      "start_time": 1201520.0,
      "end_time": 1206459.0,
      "text": "polyurethane components used in the devices cause the deletion of a subset"
    },
    {
      "index": 258,
      "start_time": 1206460.0,
      "end_time": 1211466.0,
      "text": "of immune cells when blood comes in contact with them. This predisposes the"
    },
    {
      "index": 259,
      "start_time": 1211460.0,
      "end_time": 1216061.0,
      "text": "patient to fungal and some viral infections necessitating appropriate"
    },
    {
      "index": 260,
      "start_time": 1216060.0,
      "end_time": 1220051.0,
      "text": "prophylactic therapy. Considering the multitude of risks and"
    },
    {
      "index": 261,
      "start_time": 1220060.0,
      "end_time": 1225405.0,
      "text": "lifestyle modifications associated with ventricular assist device implant, it is"
    },
    {
      "index": 262,
      "start_time": 1225400.0,
      "end_time": 1230609.0,
      "text": "important for prospective patients to be informed prior to decision making. In"
    },
    {
      "index": 263,
      "start_time": 1230610.0,
      "end_time": 1235278.0,
      "text": "addition to physician consult, various Internet-based patient directed"
    },
    {
      "index": 264,
      "start_time": 1235280.0,
      "end_time": 1238933.0,
      "text": "resources are available to assist in patient education."
    },
    {
      "index": 265,
      "start_time": 1238930.0,
      "end_time": 1243666.0,
      "text": "List of implantable VAD devices This is a partial list and may never be"
    },
    {
      "index": 266,
      "start_time": 1243670.0,
      "end_time": 1246917.0,
      "text": "completeReferenced additions are welcome See also"
    },
    {
      "index": 267,
      "start_time": 1246910.0,
      "end_time": 1249481.0,
      "text": "Intra-aortic balloon pump Gus Rosenberg"
    },
    {
      "index": 268,
      "start_time": 1249480.0,
      "end_time": 1251104.0,
      "text": "References External links"
    },
    {
      "index": 269,
      "start_time": 1251110.0,
      "end_time": 1253951.0,
      "text": "LifeFlow LVAD at the University of Virginia"
    },
    {
      "index": 270,
      "start_time": 1253950.0,
      "end_time": 1258212.0,
      "text": "Nader Moazami, Patrick M. McCarthy Temporary Circulatory Support"
    },
    {
      "index": 271,
      "start_time": 1258210.0,
      "end_time": 1263420.0,
      "text": "Eugene L. Kukuy, Mehmet C. Oz, Yoshifumi Naka Long-Term Mechanical Circulatory"
    },
    {
      "index": 272,
      "start_time": 1263420.0,
      "end_time": 1266396.0,
      "text": "Support – a review of the subject as at 2003."
    },
    {
      "index": 273,
      "start_time": 1266400.0,
      "end_time": 1269445.0,
      "text": "Mechanical Circulatory Support Resource Center"
    },
    {
      "index": 274,
      "start_time": 1269440.0,
      "end_time": 1272078.0,
      "text": "Health Center Online VAD Mayo Clinic VAD"
    },
    {
      "index": 275,
      "start_time": 1272080.0,
      "end_time": 1276140.0,
      "text": "Life without a pulse — news story about Canadian man with VAD"
    },
    {
      "index": 276,
      "start_time": 1276140.0,
      "end_time": 1281349.0,
      "text": "Heart Pump Design Could Give Patients New Hope — A new counter-flow heart pump"
    },
    {
      "index": 277,
      "start_time": 1281350.0,
      "end_time": 1284530.0,
      "text": "developed by Queensland University of Technology"
    },
    {
      "index": 278,
      "start_time": 1284530.0,
      "end_time": 1289468.0,
      "text": "Heart pump improves quality of life in congestive heart failure patients A"
    },
    {
      "index": 279,
      "start_time": 1289470.0,
      "end_time": 1294544.0,
      "text": "rapid review of the medical literature and specialist opinion as at December"
    },
    {
      "index": 280,
      "start_time": 1294540.0,
      "end_time": 1297043.0,
      "text": "2005 NATIONAL INSTITUTE FOR HEALTH AND"
    },
    {
      "index": 281,
      "start_time": 1297050.0,
      "end_time": 1301515.0,
      "text": "CLINICAL EXCELLENCE Interventional procedures overview – short-term"
    },
    {
      "index": 282,
      "start_time": 1301510.0,
      "end_time": 1306043.0,
      "text": "circulatory support with left ventricular assist devices as a bridge"
    },
    {
      "index": 283,
      "start_time": 1306040.0,
      "end_time": 1311317.0,
      "text": "to cardiac transplantation or recovery A rapid review of the medical literature"
    },
    {
      "index": 284,
      "start_time": 1311320.0,
      "end_time": 1314094.0,
      "text": "and specialist opinion as at December 2005"
    },
    {
      "index": 285,
      "start_time": 1314090.0,
      "end_time": 1318217.0,
      "text": "Courtney J. Gemmato,Matthew D. Forrester,Timothy J. Myers,O.H."
    },
    {
      "index": 286,
      "start_time": 1318220.0,
      "end_time": 1323294.0,
      "text": "Frazier,Denton A. Cooley Thirty-Five Years of Mechanical Circulatory Support"
    },
    {
      "index": 287,
      "start_time": 1323300.0,
      "end_time": 1327291.0,
      "text": "at the Texas Heart Institute Tex Heart Inst J 2005;32:168-77"
    },
    {
      "index": 288,
      "start_time": 1327290.0,
      "end_time": 1332229.0,
      "text": "MyLVAD.com Non branded site with video, news, and community discussions on"
    },
    {
      "index": 289,
      "start_time": 1332220.0,
      "end_time": 1335061.0,
      "text": "VAD&#39;s. Ventricular Assist Device Center for"
    },
    {
      "index": 290,
      "start_time": 1335070.0,
      "end_time": 1338115.0,
      "text": "Heart Failure – Northwestern Memorial Hospital"
    },
    {
      "index": 291,
      "start_time": 1338110.0,
      "end_time": 1348110.0,
      "text": "[1] Website Hannover Medical School. LVAD FAQ."
    }
  ]
}